butyl 3-(1H-tetrazol-5-yl)oxanilate

orally active antiallergic agent; structure given in first source

Also Known As:

((3-(1H-tetrazol-5-yl)phenyl)amino)oxoacetic acid N-butyl ester; WP 833; WP-833; butyl-((3-(1H-tetrazol-5-yl)phenyl)amino)oxoacetate

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - butyl 3-(1H-tetrazol-5-yl)oxanilate: 3

Related Diseases

1.	Hypersensitivity (Allergy) 04/01/1990 - "The effects of WP-833 metabolites on experimental allergic reactions were investigated in various animal models. " 01/01/1988 - "In contrast to above findings demonstrating that WP-833 clearly inhibited type I allergic reaction, systemic Forssman shock in guinea pigs and reversed cutaneous anaphylaxis in rats (type II), passive Arthus reaction in rats (type III), and contact dermatitis and tuberculin reaction in mice (type IV) were unaffected by WP-833 even in higher doses than in those capable of completely inhibiting type I allergic reaction."
2.	Shock 01/01/1988 - "In contrast to above findings demonstrating that WP-833 clearly inhibited type I allergic reaction, systemic Forssman shock in guinea pigs and reversed cutaneous anaphylaxis in rats (type II), passive Arthus reaction in rats (type III), and contact dermatitis and tuberculin reaction in mice (type IV) were unaffected by WP-833 even in higher doses than in those capable of completely inhibiting type I allergic reaction."
3.	Contact Dermatitis (Eczema, Contact) 01/01/1988 - "In contrast to above findings demonstrating that WP-833 clearly inhibited type I allergic reaction, systemic Forssman shock in guinea pigs and reversed cutaneous anaphylaxis in rats (type II), passive Arthus reaction in rats (type III), and contact dermatitis and tuberculin reaction in mice (type IV) were unaffected by WP-833 even in higher doses than in those capable of completely inhibiting type I allergic reaction."
4.	Asthma (Bronchial Asthma) 01/01/1988 - "Experimental asthma was clearly inhibited in a dose-dependent fashion by oral administration of WP-833."
5.	Arthus Reaction 01/01/1988 - "In contrast to above findings demonstrating that WP-833 clearly inhibited type I allergic reaction, systemic Forssman shock in guinea pigs and reversed cutaneous anaphylaxis in rats (type II), passive Arthus reaction in rats (type III), and contact dermatitis and tuberculin reaction in mice (type IV) were unaffected by WP-833 even in higher doses than in those capable of completely inhibiting type I allergic reaction."

Related Drugs and Biologics

1.	Tuberculin (PPD)

Related Therapies and Procedures

1.	Oral Administration